NCT04406727View on ClinicalTrials.gov

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

HIV-1 Infection

Interventions

BIOLOGICAL

UB-421

UB-421 in combination with their ARV

OTHER

Antiretroviral (ARV)

Antiretroviral (ARV)

Sponsors

Lead Sponsor

United BioPharma

All Listed Sponsors

lead

United BioPharma

INDUSTRY

NCT04406727 - UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection | Biotech Hunter | Biotech Hunter